MND patients in the UK denied access to lifesaving drug tofersen, despite Biogen supplying it free, due to NHS covering ...

Ionis and Biogen have been partnering on antisense drug development for a decade. The two companies won approval for $1.8bn (in 2022) Spinraza, indicated for Spinal Muscular Atrophy. Tofersen, ...

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1 With QALSODY, Biogen has advanced the role of neurofilament in the ...

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic ...

On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...

The Food and Drug Administration approved Tofersen, an investigational drug developed by Biogen and Ionis Pharmaceuticals, to treat a rare genetic form of amyotrophic lateral sclerosis (ALS) Tuesday ...

The Food and Drug Administration has conditionally approved a new ALS medicine in a decision likely to influence how other experimental treatments for the nerve-destroying disease are tested and ...

Health Technology Assessment (HTA) evaluations issued by Canada's Drug Agency (CDA) and the Institut national d'excellence en santé et en services sociaux (INESSS) for QALSODY (TM) (tofersen injection ...

SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would ...

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs ...